UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients

Cancers, 2021-08, Vol.13 (17), p.4281

2021

Volltextzugriff (PDF)

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359221148921-17588359221148921

2023

Volltextzugriff (PDF)

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

The Lancet (British edition), 2024-04, Vol.403 (10437), p.1649-1659

2024

Volltextzugriff (PDF)

3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

The Lancet (British edition), 2024-04, Vol.403 (10437), p.1649

2024

Volltextzugriff (PDF)

Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-19-06-OT2-19-06

2022

Volltextzugriff (PDF)

Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients

Clinical biochemistry, 2020-02, Vol.76, p.17-23

2020

Volltextzugriff (PDF)

Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.503-503

2020

Volltextzugriff (PDF)

Abstract OT2-08-02: SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT2-08-02-OT2-08-02

2023

Volltextzugriff (PDF)

Diseño de una web 2.0 para cuidadoras de personas con problemas crónicos de salud

Pixel-bit : revista de medios y educación, 2015-07 (47)

2015

Volltextzugriff (PDF)

TUTORÍA VIRTUAL PARA PROFESIONALES DE ENFERMERÍA NOVELES (A VIRTUAL BASED TUTORIAL FOR NEW NURSING PROFESSIONALS)

Revista iberoamericana de educación a distancia, 2013-06, Vol.16 (1), p.199-215

2013

Volltextzugriff (PDF)

Diseño de una web 2.0 para cuidadoras de personas con problemas crónicos de salud

Pixel-bit : revista de medios y educación, 2015 (47), p.149-161

2015

Volltextzugriff (PDF)

TUTORÍA VIRTUAL PARA PROFESIONALES DE ENFERMERÍA NOVELES

Revista iberoamericana de educación a distancia, 2013-01, Vol.16 (1)

2013

Volltextzugriff (PDF)

Factores sociológicos que influyen en el desarrollo de la depresión en las mujeres

Anuario de hojas de warmi : per al feminisme, la cooperació i la solidaritat, 2011 (16)

2011

Volltextzugriff (PDF)

Dificultades de integración social en personas depresivas con pensamientos de suicidio

Index de enfermería, 2011-06, Vol.20 (1-2), p.51-55

2011

Volltextzugriff (PDF)

Dificultades de integración social en personas depresivas con pensamientos de suicidio

Index de Enfermería, 2011-06, Vol.20 (1-2), p.51-55

2011

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(20)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(6)
Science & Technology
(6)
Breast Cancer
(5)
Erbb-2 Protein
(4)
Metabolism
(4)
Adult
(3)
Chemotherapy
(3)
Endocrine Therapy
(3)
Female
(3)
Humans
(3)
Middle Aged
(3)
Oncology
(3)
Patients
(3)
Trastuzumab
(3)
Adverse Events
(2)
Aged
(2)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(2)
Breast Neoplasms - Drug Therapy
(2)
Cancer Therapies
(2)
Carboplatin
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)

3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

Optimal [ 18 F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL

Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients

Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial

Abstract OT2-08-02: SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive metastatic breast cancer (MBC)

Quality of life with palbociclib plus fulvestrant placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Diseño de una web 2.0 para cuidadoras de personas con problemas crónicos de salud

TUTORÍA VIRTUAL PARA PROFESIONALES DE ENFERMERÍA NOVELES (A VIRTUAL BASED TUTORIAL FOR NEW NURSING PROFESSIONALS)

Diseño de una web 2.0 para cuidadoras de personas con problemas crónicos de salud

TUTORÍA VIRTUAL PARA PROFESIONALES DE ENFERMERÍA NOVELES

Factores sociológicos que influyen en el desarrollo de la depresión en las mujeres

Dificultades de integración social en personas depresivas con pensamientos de suicidio

Dificultades de integración social en personas depresivas con pensamientos de suicidio

Suchergebnisse filtern